can anybody tell me what tdx has going for its, page-7

Cashngrab

"Is there any legal action to Bayer, TDX can't seek a settlement, there was no real contract agreement to sell Seedex, all i see is Bayer basically pulled the plug"

Think your getting your wires crossed, Bayer = Readrite = Wheat Test and there was contracts between parties. No legal action just quiet friendly settlement.


"Re the TB, there is no sales only research use ATM, so sales along way off IMO"

Neoclone is in the business of Selling Antibodies / markers for use in Research.

Both Announcements below


SpeeDx Deal

SYDNEY, Australia 13 December 2011: Tyrian Diagnostics Limited (“Tyrian”) announced today
that it has entered an exclusive licence agreement with SpeeDx Pty Ltd (“SpeeDx”) for the
development and commercialization of tests to diagnose active tuberculosis (TB) using Tyrian’s
patented molecular biomarker.
Under its agreement with SpeeDx, Tyrian will receive an up-front payment, milestone payments
upon the achievement of regulatory and patent milestones, a percentage of sub-licensing revenues
and royalties on net sales of products incorporating Tyrian’s patented intellectual property. In
addition, SpeeDx will pay all patent and research and development costs.
SpeeDx’s proprietary MNAzyme technology allows the simultaneous and sensitive detection of
multiple DNA or RNA biomarkers from a clinical sample. It is anticipated that Tyrian’s biomarker will
be used in combination with other indicator molecules, such as those allowing analysis of drug
resistance, to deliver enabling information for both the diagnosis and treatment of active TB in a
single test.
Tyrian’s Managing Director, Dr Jenny Harry, said “We are very pleased to announce that we have
exclusively licensed development of our molecular TB test to SpeeDx, and we believe that the
combination of our novel biomarker and its technology should result in a highly competitive product.
This licence is part of our strategy to secure partners for the assets we have developed.”
A validation study, conducted in 2010 at the Public Health Research Institute’s TB Centre in the US,
showed Tyrian’s biomarker has the potential to provide improved sensitivity over existing RNAbased
tests for direct detection of active TB infection in sputum samples. The biomarker was also
found to be conserved across different clinical strains of TB, including multi-drug resistance strains.
Tyrian does not have the technology to develop a molecular TB test, so sought a partner with the
appropriate expertise to develop a test using its mRNA biomarker.
Over the past 12 months, Tyrian has engaged with a number of diagnostic companies interested in
accessing new biomarkers to diagnose active TB for implementation onto their molecular diagnostic
test platforms. The Company elected to partner with SpeeDx, an Australian-based company,
because SpeeDx’s sensitive and highly selective technology, and its ability to be adapted to many
different molecular diagnostic platforms, would potentially enable a broad commercialization
strategy for products incorporating Tyrian’s biomarker.

Neoclone Deal

SYDNEY, Australia 19 December 2011: Tyrian Diagnostics Limited (“Tyrian”) announced today
that it has signed an exclusive distribution agreement with NeoClone LLC (“NeoClone”) for the
manufacture and distribution of antibodies it has developed to detect TB proteins, including
antibodies to Tyrian’s lead TB protein biomarker.
Under this agreement, Tyrian will receive 40% of gross income on products sold. NeoClone will pay
all costs associated with the manufacture, marketing and distribution of the antibodies, which will be
sold for research uses only. Tyrian retains the sole rights to grant licences to third parties to use the
antibodies for development and sale of products for other commercial purposes.
Based in Madison, Wisconsin (USA), NeoClone is a quality provider of antibodies and distributes a
portfolio of antibodies that detect a range of clinical diagnostic targets in the oncology, CNS and
infectious disease areas. NeoClone was previously engaged by Tyrian to develop antibodies to a
select group of Tyrian’s TB protein biomarkers, including its lead TB protein biomarker. These
antibodies were used by Tyrian to develop specific diagnostic assays for eight TB proteins it
discovered in TB-infected sputum samples.
Tyrian’s Managing Director, Dr Jenny Harry, said “We are delighted to appoint NeoClone as the
preferred provider of Tyrian’s TB antibodies for research purposes. This agreement ensures that
third parties can access Tyrian’s proprietary antibodies to fully explore the potential for sensitive TB
assays on a variety of diagnostic platforms. The Company previously reported that currently
available, rapid Point-of-Care diagnostic systems lack the sensitivity to detect TB proteins in sputum
or blood. With further advances in the pipeline for Point of Care diagnostic technologies there is
potential for significant improvements in sensitivity that may result in entirely new tests becoming
possible for the rapid and accurate detection of active TB using Tyrian’s antibodies.”
Tyrian is continuing discussions with third parties for the sale or licence of its TB protein intellectual
property for the development of such tests. This agreement with NeoClone adds to our recent
announcement on a licence agreement with Australian company Speedx for the development of
molecular-based tests for active TB.